Solid-phase synthesis of hydroxamic acid based TNF-α convertase inhibitors

Tetrahedron

Volumn 55, Issue 23, 1999, Pages 7221-7232

  Barlaam, Bernard ^a   Koza, Patrice ^a   Berriot, Julien ^a  

^a Zeneca Pharma   (France)

Author keywords

Acylation; Hydroxamic acid; Reductive amination; Solid phase synthesis

Indexed keywords

HYDROXAMIC ACID; RESIN; SASRIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACYLATION; AMINATION; ARTICLE; CHEMICAL ANALYSIS; CHEMICAL REACTION; DERIVATIZATION; DRUG STRUCTURE; DRUG SYNTHESIS; PRIORITY JOURNAL; REACTION ANALYSIS; SOLID STATE; STRUCTURE ANALYSIS;

EID: 0033523078     PISSN: 00404020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0040-4020(99)00347-6     Document Type: Article

References (28)

1. This work was presented in part at the "Journées de Chimie Organique" meeting (September 15-17, 1998, Palaiseau, France), abstract n° A 153
2. a) Beckett, R.P.; Davidson, A.H.; Drummond, A.H.; Huxley, P.; Whittaker, M. Drug Discovery Today 1996, 1, 16
3. b) Beckett, R.P.; Whittaker, M. Exp. Opin. Ther. Patents 1998, 8, 259
4. c) Hagmann, W.K.; Lak, M.W.; Becker, J.W. in Ann. Rep. Med. Chem, Bristol, J.A. (Ed) Academic Press Inc 1996, Vol. 31, 231
5. Barlaam, B.; Hamon, A.; Maudet, M. Tetrahedron Lett. 1998, 39, 7865.
6. Isolation of TACE: a) Black, R.A. and al. Nature 1997, 385, 729
7. b) Moos, M.L. and al. Nature 1997, 385, 733
8. During the course of this work, resin 1 was mentioned briefly by Richter (ref. 5b) and Gordeev (ref 5i). For recent papers on solid phase synthesis of hydroxamic acids: a) Floyd, C.; Lewis, C.; Patel, S.R.; Whittaker, M. Tetrahedron Lett. 1996, 37, 8045
9. b) Richter, S.L.; Desai, M.C. Tetrahedron Lett. 1997, 38, 321
10. c) Bauer, U.; Ho, W.B.; Koskinen, A.M.P. Tetrahedron Lett. 1997, 38, 7233
11. d) Mellor, S.L.; McGuire, C.; Chan, W.C. Tetrahedron Lett. 1997, 38, 3311
12. e) Gu, K.N.; Patel, D.V. J. Org. Chem. 1997, 62, 7088
13. f) Chen, J.J.; Spatola, A.F. Tetrahedron Lett. 1997, 38, 1511
14. g) McGeehan, G.M et al. PCT Int. Appl. WO97/24117 (Rhone-Poulenc Rorer); Chem. Abst. 127:161589
15. h) Dankwardt, S.M. Synlett, 1998, 761
16. i) Gordeev, M.F.; Hui, H.C.; Gordon, E.M.; Patel, D.V. Tetrahedron Lett. 1997, 38, 1729
17. Broadhurst, M.J.; Brown, P.A.; Johnson, W.H.; Lawton, G. Eur. Pat. Appl., EP 497192 (Roche); Chem. Abst. 118:169601
18. Stork, G.; Leong, A.Y.W.; Tourin, A.M. J. Org. Chem. 1976, 41, 3491
19. H1,H2 = 5.9 Hz).
20. Loading of resin 3 may vary from batch to batch. Yields have been calculated with loading of resin 3 set to 0.5 mmol/g. Compounds 2a-c have been isolated without further purification; they may contain traces of solvents and/or minor impurities. All these factors may explain that yields were found greater than 100% in some cases.
21. Salvi, J.P.; Walchsofer, N.; Paris, J. Tetrahedron Lett. 1994, 35, 1181
22. Look, G.C.; Murphy, M.M.; Campbell, D.A.; Gallop, G.A. Tetrahedron Lett. 1995, 36, 2937
23. Harmon has previously shown that reaction of α-amino hydroxamic acids with aldehydes gave the corresponding imidazolinones: Harmon, R.E.; Rizzo, V.L.; Gupta, S.K. J. Heterocycl. Chem. 1970, 7, 439
24. a) Barlaam, B PCT Int. Appl. WO 9807742 (Zeneca); Chem. Abst. 128:205148. Biological activities of these MMP/TACE inhibitors will be reported elsewhere in due course;
25. b) For the synthesis of similar compounds in solution, see: Alpegiani, M.; Abrate, F.; Bissolino, P.; Palladino, M.; Perrone, E. PCT Int. Appl. WO 9749674 (Pharmacia-Upjohn); Chem. Abst. 128:089110. In this patent, Alpegiani et al. reported a adduct similar to 17 with acetone.
26. Mergler, M.; Tanner, R.; Gosteli J.; Grogg, P. Tetrahedron Lett., 1988, 29, 4005
27. O'Donnell, M.J.; Polt R.L. J. Org. Chem. 1982, 47, 2663
28. Kobayashi, S.; Iimori, T.; Izawa, T.; Ohno, M. J. Am. Chem. Soc. 1981, 103, 2406